Payment overview · 2025
General Payments
$1,221.76
39 reported records · 12 companies
Healthcare provider profile · identity verified
Rafael Espinet Perez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PONCE, PR · NPI 1487845780
Verified facts
What the public records show
CMS Open Payments records show Rafael Espinet Perez, M.D. received $1,221.76 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 728 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Bayer Puerto Rico Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 784 records involving 303 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 147 records involving 126 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $403.56 | 33.0% | 17 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $193.69 | 15.8% | 4 | 2025 |
| Bayer Puerto Rico Inc. | Unresolved — no canonical attribution shown | $148.42 | 12.2% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $123.81 | 10.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$109.89 | 9.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $60.44 | 5.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.71 | 4.6% | 2 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $51.48 | 4.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.06 | 1.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.85 | 1.6% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $19.35 | 1.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.50 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,221.76 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc., Bayer Puerto Rico Inc. | $272.23 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $249.99 | 11 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $193.69 | 4 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $109.89 | 1 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $60.44 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $56.71 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PBG PUERTO RICO LLC | $37.60 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PBG PUERTO RICO LLC | $33.73 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PBG PUERTO RICO LLC | $33.73 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| CLEVIPREX Normalized: cleviprex |
Drug | Chiesi USA, Inc. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 133 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 728 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
728 | 162 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
201 | 45 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Puerto Rico Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 784 supporting records · 303 recipient NPIs · example record 1225435793 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 38 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 38 |
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 147 supporting records · 126 recipient NPIs · example record 1228798592 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Famotidine | Famotidine | 1391 | 367 |
| Gabapentin | Gabapentin | 821 | 227 |
| Atorvastatin Calcium | Atorvastatin Calcium | 741 | 286 |
| Synthroid | Levothyroxine Sodium | 728 | 162 |
| Losartan Potassium | Losartan Potassium | 614 | 211 |
| Pantoprazole Sodium | Pantoprazole Sodium | 526 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 471 | 176 |
| Metoprolol Succinate | Metoprolol Succinate | 455 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 449 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 151 |
| Metformin Hcl | Metformin Hcl | 331 | 128 |
| Clonazepam | Clonazepam | 327 | 71 |
| Lisinopril | Lisinopril | 298 | 114 |
| Fluticasone Propionate | Fluticasone Propionate | 295 | 158 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 284 | 66 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 278 | 96 |
| Clopidogrel | Clopidogrel Bisulfate | 265 | 94 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 95 |
| Carvedilol | Carvedilol | 224 | 82 |
| Farxiga | Dapagliflozin Propanediol | 201 | 45 |
| Omeprazole | Omeprazole | 201 | 53 |
| Nifedipine Er | Nifedipine | 191 | 66 |
| Pregabalin | Pregabalin | 183 | 37 |
| Glimepiride | Glimepiride | 179 | 65 |
| Montelukast Sodium | Montelukast Sodium | 168 | 62 |
| Simvastatin | Simvastatin | 166 | 66 |
| Furosemide | Furosemide | 165 | 70 |
| Ezetimibe | Ezetimibe | 163 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 60 |
| Temazepam | Temazepam | 146 | 22 |
| Valsartan | Valsartan | 143 | 52 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 136 | 30 |
| Eliquis | Apixaban | 133 | 38 |
| Allopurinol | Allopurinol | 116 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 116 | 37 |
| Irbesartan | Irbesartan | 115 | 33 |
| Meclizine Hcl | Meclizine Hcl | 114 | 50 |
| Azithromycin | Azithromycin | 111 | 97 |
| Trazodone Hcl | Trazodone Hcl | 107 | 28 |
| Alendronate Sodium | Alendronate Sodium | 103 | 29 |
| Donepezil Hcl | Donepezil Hcl | 103 | 40 |
| Prednisone | Prednisone | 102 | 65 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 101 | 15 |
| Finasteride | Finasteride | 100 | 39 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 99 | 65 |
| Latanoprost | Latanoprost | 97 | 31 |
| Baclofen | Baclofen | 96 | 84 |
| Methylprednisolone | Methylprednisolone | 95 | 83 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 33 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 88 | 24 |
| Nabumetone | Nabumetone | 82 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 30 |
| Fenofibrate | Fenofibrate | 77 | 32 |
| Levetiracetam | Levetiracetam | 77 | 14 |
| Memantine Hcl | Memantine Hcl | 76 | 24 |
| Chlorthalidone | Chlorthalidone | 75 | 22 |
| Humalog | Insulin Lispro | 74 | 15 |
| Sertraline Hcl | Sertraline Hcl | 74 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 27 |
| Dexamethasone | Dexamethasone | 66 | 63 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 29 |
| Atenolol | Atenolol | 61 | 22 |
| Jardiance | Empagliflozin | 61 | 21 |
| Spironolactone | Spironolactone | 61 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | 18 |
| Tradjenta | Linagliptin | 57 | 18 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 56 | 16 |
| Lansoprazole | Lansoprazole | 56 | 12 |
| Buspirone Hcl | Buspirone Hcl | 55 | 12 |
| Brilinta | Ticagrelor | 54 | 15 |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 54 | suppressed |
| Levofloxacin | Levofloxacin | 54 | 47 |
| Ozempic | Semaglutide | 54 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 23 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 53 | suppressed |
| Lorazepam | Lorazepam | 52 | 11 |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 45 | 12 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | 15 |
| Alprazolam | Alprazolam | 43 | suppressed |
| Mounjaro | Tirzepatide | 42 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 40 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 40 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | 13 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 39 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 37 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 35 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 12 |
| Synjardy | Empagliflozin/Metformin Hcl | 35 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | 16 |
| Indapamide | Indapamide | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | 11 |
| Jentadueto | Linagliptin/Metformin Hcl | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 28 |
| Clotrimazole | Clotrimazole | 30 | 18 |
| Enalapril Maleate | Enalapril Maleate | 29 | 16 |
| Folic Acid | Folic Acid | 29 | suppressed |
| Glipizide | Glipizide | 29 | 13 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 29 | suppressed |
| Ciclopirox | Ciclopirox | 28 | 22 |
| Risperidone | Risperidone | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 12 |
| Ciclopirox | Ciclopirox Olamine | 27 | 23 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 27 | 24 |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 25 |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Ramipril | Ramipril | 25 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 22 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Orphenadrine Citrate | Orphenadrine Citrate | 20 | 17 |
| Benzonatate | Benzonatate | 19 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 19 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 19 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | 13 |
| Cilostazol | Cilostazol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 14 |
| Colchicine | Colchicine | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 16 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Sulindac | Sulindac | 15 | 12 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 13 |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Easy Touch | Syring-Needl,disp,insul,0.3 Ml | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Estazolam | Estazolam | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,221.76 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AURORA EV-ICD MRI SURESCAN, CLEVIPREX, Dexcom G6 Transmitter, ELIQUIS, EMBLEM MRI S-ICD, EVENITY, JARDIANCE, Kerendia, NURTEC ODT, PROLIA, SYNTHROID, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error